ArticleMedicine2026
Serum CEACAM6 and CEACAM8 as predictors of poor outcome in pediatric Mycoplasma pneumoniae pneumonia: A single-center prospective cohort study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to evaluate the prognostic utility of serum carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) and CEACAM8 levels in children with Mycoplasma pneumoniae pneumonia (MPP). This single-center prospective cohort study enrolled 364 children with confirmed MPP and 160 age-matched healthy controls between February 2023 and May 2025. Serum levels of CEACAM6, CEACAM8, lactate dehydrogenase (LDH), D-dimer, interleukin-6, C-reactive protein, and myeloperoxidase were measured at admission using enzyme-linked immunosorbent assay. Patients were classified into good- (n = 295) or poor-prognosis (n = 69) groups after 1 week of standardized azithromycin therapy based on clinical, radiological, and spirometric criteria. Multivariable logistic regression was used to identify independent predictors of poor outcome. Receiver-operating characteristic curve analysis assessed the predictive performance of CEACAM6 and CEACAM8, individually and in combination, with corresponding areas under the curve. Correlations with inflammatory markers were evaluated using the Spearman rank correlation test. Children with poor outcomes had significantly higher CEACAM6 and CEACAM8 levels at admission (both P < .001). Multivariable analysis identified elevated CEACAM6 (odds ratio = 1.12, 95% confidence interval = 1.05-1.19) and CEACAM8 (odds ratio = 1.09, 95% confidence interval = 1.03-1.15) as independent predictors of poor prognosis. Receiver-operating characteristic analysis demonstrated areas under the curve of 0.771 for CEACAM6, 0.755 for CEACAM8, and 0.826 for their combination. Both biomarkers correlated positively with interleukin-6, C-reactive protein, and myeloperoxidase (all P < .01) and declined significantly after treatment. Serum CEACAM6 and CEACAM8 are independently associated with poor outcomes in pediatric MPP. Their combined use enhances prognostic accuracy and may support early risk stratification in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.